Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Monday, April 21 2014 11:07am ET - U.S. Markets close in 4 hours and 53 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > Biogen Idec Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Biogen Idec Inc. Company Profile
With its pipeline full of biotech drugs, Biogen Idec aims to meet the unmet needs of patients around the world. The biotech giant is focused on developing treatments in the areas of immunology and neurology. Its product roster includes best-selling Avonex, a popular drug for the treatment of relapsing multiple sclerosis (MS); Tysabri, a drug treatment for MS and Crohn's disease; Rituxan, a monoclonal antibody developed jointly with Genentech that treats non-Hodgkin's lymphoma and rheumatoid arthritis; and Fumaderm, a psoriasis drug marketed in Germany. Biogen Idec serves customers in more than 90 countries.
Headlines for Biogen Idec Inc.
Biogen signs Factor VIII license agreement with Amunix
- 2 hours, 50 minutes ago
8:04 am Biogen Idec signs license agreement with Amunix for XTENylated Factor VIII
- Mon 8:04 am ET
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
Marketwire - Mon 8:00 am ET
[$$] Preview
at Barrons.com - Sat Apr 19
More Headlines...
More on Biogen Idec Inc.
Quote Msgs
Chart Insider
News Financials
Profile Analyst Ratings
Reports    
Research    
Contact Information
Address: 133 Boston Post Rd.
Weston, MA 02493
Phone:781-464-2000
Fax:
Financial Highlights
Fiscal Year End:December
Revenue (2013):6932.20 M
Revenue Growth (1 yr):25.70%
Employees (2013):6,850
Employee Growth (1 yr):15.10%
Key People
Chairman of Board: Stelios Papadopoulos
CEO and Director: George A. Scangos
EVP Finance and CFO: Paul J. Clancy
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
Bayer Pharma AG
Merck Serono S.A.
Pfizer Inc.
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?